TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36958365

Group type: EXPERIMENTAL
Intervention: ART started before 2015
Number of subjects: 206891

Group type: EXPERIMENTAL
Intervention: ART started after 2015
Number of subjects: 206891

Group type: EXPERIMENTAL
Intervention: ART started before 2015 with CD4 < 49 cells/μL
Number of subjects: 206891

Group type: EXPERIMENTAL
Intervention: ART started after 2015 with CD4 < 49 cells/μL
Number of subjects: 206891

Group type: EXPERIMENTAL
Intervention: ART started before 2015 with CD4 ≥ 500 cells/μL
Number of subjects: 206891

Group type: EXPERIMENTAL
Intervention: ART started after 2015 with CD4 ≥ 500 cells/μL
Number of subjects: 206891
Study: 36958363

Group type: EXPERIMENTAL
Intervention: Low calorie and protein targets (6 kcal/kg per day and 0.2-0.4 g/kg per day protein)
Number of subjects: 3044

Group type: COMPARATOR
Intervention: Standard calorie and protein targets (25 kcal/kg per day and 1.0-1.3 g/kg per day protein)
Number of subjects: 3044

Group type: EXPERIMENTAL
Intervention: Low calorie and protein targets
Number of subjects: 3044

Group type: COMPARATOR
Intervention: Standard calorie and protein targets
Number of subjects: 3044
Study: 36958391

Group type: EXPERIMENTAL
Intervention: Transcatheter Left Ventricular Restoration (AccuCinch System)
Number of subjects: 51
Study: 36958470

Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36958473

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy algorithm incorporating the respiratory exchange ratio
Number of subjects: 350

Group type: COMPARATOR
Intervention: Current hemodynamic guidelines (Control)
Number of subjects: 350
Study: 36958479

Group type: EXPERIMENTAL
Intervention: Venefit (Closurefast)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Radiofrequency Induced Thermal Therapy (RFITT)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Endovenous Radiofrequency (EVRF)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Venefit
Number of subjects: 172

Group type: COMPARATOR
Intervention: RFITT
Number of subjects: 172

Group type: COMPARATOR
Intervention: EVRF
Number of subjects: 172
Study: 36958668

Group type: EXPERIMENTAL
Intervention: Neck MFI in the Recovered group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Leg MFI in the Mild group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Traumatic Injury Distress Scale (TIDS) and neck MFI at 1-week postinjury
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lower extremity torques
Number of subjects: 97
Study: 36958702

Group type: EXPERIMENTAL
Intervention: Skills TO Manage Pain (STOMP) intervention, a 12-week program including group sessions, one-on-one pain self-management sessions, and peer leaders.
Number of subjects: 280

Group type: COMPARATOR
Intervention: Enhanced usual care (control group).
Number of subjects: 280
Study: 36958720

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 36958740

Group type: EXPERIMENTAL
Intervention: Kilkari mobile messaging programme
Number of subjects: 10000000
Study: 36958766

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg two times per day
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg two times per day
Number of subjects: 816

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (AEs) with tofacitinib 5 mg
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (AEs) with tofacitinib 10 mg
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Persistence of treatment
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Minimal disease activity (MDA) achievement
Number of subjects: 816
Study: 36958777

Group type: EXPERIMENTAL
Intervention: Observational longitudinal registry data collection
Number of subjects: 500
Study: 36958792

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) for 2 hours
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 108
Study: 36958796

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg every 4 months through month 20)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/day, tapered after month 24)
Number of subjects: 188
Study: 36958940

Group type: EXPERIMENTAL
Intervention: High plasma ferritin (˃55.7 ng/mL) and high triglyceride (˃1.9 mmoL/L)
Number of subjects: 2071

Group type: EXPERIMENTAL
Intervention: Ferritin levels
Number of subjects: 2071

Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 2071

Group type: EXPERIMENTAL
Intervention: Triglyceride as a mediator
Number of subjects: 2071
Study: 36958969

Group type: EXPERIMENTAL
Intervention: Mediterranean diet group (MDG, n=59)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle group (MLG, n=59)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard care group (SCG, n=62)
Number of subjects: 180
Study: 36958977

Group type: EXPERIMENTAL
Intervention: Self-administered stretching exercises
Number of subjects: 100

Group type: COMPARATOR
Intervention: Motor control exercises
Number of subjects: 100
Study: 36958998

Group type: EXPERIMENTAL
Intervention: d-serine 80 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: d-serine 100 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: d-serine 120 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 36959289

Group type: EXPERIMENTAL
Intervention: Biomarkers of inflammation and coagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumoproteins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36959430

Group type: EXPERIMENTAL
Intervention: DO-MoST (patient-centered, motivational approach to shared decision making)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DO-MoST
Number of subjects: 20
Study: 36959540

Group type: EXPERIMENTAL
Intervention: 7 weeks external beam radiotherapy (EBRT) and 3 years androgen deprivation therapy (ADT) with one concurrent cycle of systemic treatment (three, six, or nine GBq)
Number of subjects: 0
Study: 36959584

Group type: EXPERIMENTAL
Intervention: Clinical, laboratory, and imaging biomarkers assessment in SMuRF-less patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive transthoracic echocardiographic assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiographic parameters assessment using the SYNTAX score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariable linear and logistic regression models
Number of subjects: 0
Study: 36959613

Group type: EXPERIMENTAL
Intervention: Home-based cardio-oncology rehabilitation (CORE) using a telerehabilitation approach for 12 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Home-based CORE intervention
Number of subjects: 11
Study: 36959618

Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-Control (non-therapeutic resistance RMT)
Number of subjects: 0
Study: 36959624

Group type: EXPERIMENTAL
Intervention: Active school transport (AST)
Number of subjects: 1070
Study: 36959634

Group type: EXPERIMENTAL
Intervention: Iron group (micronutrient powder with 12.5 mg of iron daily)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Noniron group (micronutrient powder without iron)
Number of subjects: 860
Study: 36959636

Group type: EXPERIMENTAL
Intervention: GloveCare (non-sterile gloves plus hand hygiene)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard care (hand hygiene alone)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Glove compliance
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Late-onset infections (LOI)
Number of subjects: 750
Study: 36959658

Group type: EXPERIMENTAL
Intervention: Perirenal fat modification (PFM) intervention using focused power ultrasound (FPU)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham-procedure
Number of subjects: 200
Study: 36959664

Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy at hysterectomy
Number of subjects: 0
Study: 36959672

Group type: EXPERIMENTAL
Intervention: Autologous leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available fibrin sealants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-PRF and commercially available fibrin sealants
Number of subjects: 0
Study: 36959874

Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Long-acting injectable antipsychotics (LAIs)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Switching from LAIs to oral antipsychotic medications
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Switching from shorter to longer injection interval LAIs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Telepsychiatry services
Number of subjects: 35
Study: 36959953

Group type: EXPERIMENTAL
Intervention: Creating Affiliations, Learning, and Mindfulness (CALM) for IVF
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 36959966

Group type: EXPERIMENTAL
Intervention: Urine E3G monitoring
Number of subjects: 30

Group type: COMPARATOR
Intervention: Serum E2 monitoring
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Matched daily samples of urine E3G and serum E2
Number of subjects: 30
Study: 36960054

Group type: EXPERIMENTAL
Intervention: RRx-001 + nivolumab
Number of subjects: 12
Study: 36960087

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 genomic sequencing performed locally for outbreak cases
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 genomic sequencing
Number of subjects: 59
Study: 36960471

Group type: EXPERIMENTAL
Intervention: Lasso logistics regression (LLR) model
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: Random forest (RF) model
Number of subjects: 3392

Group type: EXPERIMENTAL
Intervention: Extreme gradient boosting (XGBoost) model
Number of subjects: 3392

Group type: COMPARATOR
Intervention: Reference AKICS score
Number of subjects: 3392
Study: 36960538

Group type: EXPERIMENTAL
Intervention: Vonoprazan (VPZ) 20 mg
Number of subjects: 340

Group type: COMPARATOR
Intervention: Proton Pump Inhibitors (PPI) - Lansoprazole 30 mg or Esomeprazole 20 mg
Number of subjects: 340
Study: 36960716

Group type: EXPERIMENTAL
Intervention: Pocket wash (500 mL antibiotic solution) and postoperative antibiotics for 3 days along with standard prophylactic measures (chlorhexidine skin preparation, intravenous antibiotics, and TYRX-a antibiotic envelope)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Standard prophylactic measures (chlorhexidine skin preparation, intravenous antibiotics, and TYRX-a antibiotic envelope)
Number of subjects: 1010
Study: 36960730

Group type: EXPERIMENTAL
Intervention: Percutaneous epicardial substrate ablation with electroanatomical mapping
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Percutaneous epicardial substrate ablation
Number of subjects: 159
Study: 36960762

Group type: EXPERIMENTAL
Intervention: Glove Rehabilitation Application for Stroke Patients (GRASP) virtual reality home exercise program (HEP), used 4 times per week for 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual and customary care controls, details not specified.
Number of subjects: 0
Study: 36960766

Group type: EXPERIMENTAL
Intervention: Same day discharge (SDD)
Number of subjects: 7181

Group type: COMPARATOR
Intervention: Overnight observation
Number of subjects: 7181
Study: 36960779

Group type: EXPERIMENTAL
Intervention: Intraoperative enteral nutrition feeding (100 kcal/100 mL at 10-20 mL/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 28
Study: 36961017

Group type: EXPERIMENTAL
Intervention: venlafaxine for 12 weeks
Number of subjects: 438
Study: 36961086

Group type: EXPERIMENTAL
Intervention: Intracranial Aneurysms in Patients with ADPKD
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Population
Number of subjects: 0
Study: 36961220

Group type: EXPERIMENTAL
Intervention: Core decompression with autologous osteoblastic cell transplantation (5 mL with 20 x 10^6 cells/mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Core decompression with placebo (5 mL of solution without cells)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Core decompression with autologous osteoblastic cell transplantation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Core decompression with placebo
Number of subjects: 54
Study: 36961228

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36961347

Group type: EXPERIMENTAL
Intervention: Nocebo effects (conditioning and verbal suggestions)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Conditioning and verbal suggestions
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Subgroup analyses (type of sensory stimulation)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Risk of bias
Number of subjects: 37
Study: 36961348

Group type: EXPERIMENTAL
Intervention: Capnometry-Assisted Respiratory Training (CART) to raise P co2
Number of subjects: 120

Group type: COMPARATOR
Intervention: Feedback to slow respiratory rate (SLOW)
Number of subjects: 120
Study: 36961410

Group type: EXPERIMENTAL
Intervention: Medical cannabis use after certification
Number of subjects: 0
Study: 36961591

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT) with patients having major stress levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT) with patients having avoidance coping strategies
Number of subjects: 90
Study: 36961596

Group type: EXPERIMENTAL
Intervention: Vagal flexibility (VF) measured across social stressor tasks
Number of subjects: 151

Group type: COMPARATOR
Intervention: Children meeting diagnostic criteria for social anxiety disorder
Number of subjects: 151
Study: 36961650

Group type: EXPERIMENTAL
Intervention: Ari 2MRTU 960 (960 mg) every 56 ± 2 days (four injections scheduled)
Number of subjects: 266

Group type: COMPARATOR
Intervention: AOM 400 (400 mg) every 28 ± 2 days (eight injections scheduled)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Ari 2MRTU 960
Number of subjects: 266

Group type: COMPARATOR
Intervention: AOM 400
Number of subjects: 266
Study: 36961653

Group type: EXPERIMENTAL
Intervention: Setmelanotide treatment
Number of subjects: 19
Study: 36961654

Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg weekly
Number of subjects: 413

Group type: COMPARATOR
Intervention: Real-world physician's choice of therapy (RWPC)
Number of subjects: 413
Study: 36961726

Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 500
Study: 36962125

Group type: EXPERIMENTAL
Intervention: Andilaye intervention
Number of subjects: 1589

Group type: COMPARATOR
Intervention: Standard of care sanitation and hygiene programming (CLTSH)
Number of subjects: 1589
Study: 36962306

Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children-for Caregivers (ICC-C)
Number of subjects: 156
Study: 36962504

Group type: EXPERIMENTAL
Intervention: Ramadan fasting
Number of subjects: 913
Study: 36962510

Group type: EXPERIMENTAL
Intervention: Fast Track (FT) service delivery model
Number of subjects: 905

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 905
Study: 36962514

Group type: EXPERIMENTAL
Intervention: PCC with P4P
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: PCC without P4P
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Long term OAT (>3 months)
Number of subjects: 818

Group type: COMPARATOR
Intervention: SATC (treatment as usual)
Number of subjects: 818
Study: 36962656

Group type: EXPERIMENTAL
Intervention: Cash transfer only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined cups plus cash transfer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cup only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 36962671

Group type: EXPERIMENTAL
Intervention: WHO eTB RecMap
Number of subjects: 244

Group type: COMPARATOR
Intervention: Conventional WHO website
Number of subjects: 244
Study: 36962680

Group type: EXPERIMENTAL
Intervention: Plan and commit intervention
Number of subjects: 1478

Group type: COMPARATOR
Intervention: Enhanced usual care intervention
Number of subjects: 1478

Group type: COMPARATOR
Intervention: Standard protocol (control)
Number of subjects: 1478
Study: 36962700

Group type: EXPERIMENTAL
Intervention: LIVE intervention (educational 3D world)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control website (diabetes self-management education and support)
Number of subjects: 211
Study: 36962706

Group type: EXPERIMENTAL
Intervention: Rectal artesunate (RAS) pre-referral treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community Access to Rectal Artesunate for Malaria (CARAMAL) project
Number of subjects: 0
Study: 36962786

Group type: EXPERIMENTAL
Intervention: Monthly follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (weekly follow-up)
Number of subjects: 0
Study: 36962830

Group type: EXPERIMENTAL
Intervention: IMARA-SA intervention group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 59
Study: 36962838

Group type: EXPERIMENTAL
Intervention: 20μg/20μg (fractional dose) of BNT162b2
Number of subjects: 145

Group type: COMPARATOR
Intervention: 30μg/30μg (full dose) of BNT162b2
Number of subjects: 145

Group type: COMPARATOR
Intervention: Comparison of reduced dose to full dose
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Overall safety
Number of subjects: 145
Study: 36962857

Group type: EXPERIMENTAL
Intervention: Reactive focal drug administration (RFDA)
Number of subjects: 6276

Group type: COMPARATOR
Intervention: Reactive focal test and treat (RFTAT)
Number of subjects: 6276
Study: 36962912

Group type: EXPERIMENTAL
Intervention: Low Quality of Life (LQoL) group
Number of subjects: 3998

Group type: COMPARATOR
Intervention: High Quality of Life (HQoL) group
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: Adverse experiences in LQoL group
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: Menstrual problems in LQoL group
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: Follow-up of LQoL group
Number of subjects: 3998
Study: 36962953

Group type: EXPERIMENTAL
Intervention: Baseline seroprevalence of IgG antibodies to SARS-CoV-2
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Seroconversion rates
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Change in IgG concentration
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Symptom reporting
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 525
Study: 36962956

Group type: EXPERIMENTAL
Intervention: Community Engagement (CE) strategy
Number of subjects: 19169
Study: 36963004

Group type: EXPERIMENTAL
Intervention: ART/VL
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Semen Washing (SW)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vaginal Insemination (VI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall Safer Conception Program
Number of subjects: 46
Study: 36963067

Group type: EXPERIMENTAL
Intervention: Postpartum IUD (PPIUD) counselling and insertion intervention
Number of subjects: 0
Study: 36963078

Group type: EXPERIMENTAL
Intervention: bCPAP device
Number of subjects: 14
Study: 36963116

Group type: EXPERIMENTAL
Intervention: Deep learning enabled MV-based real-time image guided radiation therapy
Number of subjects: 0
Study: 36963127

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 49
Study: 36963200

Group type: EXPERIMENTAL
Intervention: Gemcitabine and nab-paclitaxel every other week
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) and liposomal irinotecan (nal-IRI) every other week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 0
Study: 36963203

Group type: EXPERIMENTAL
Intervention: Virtual reality (PABLO system)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 37
Study: 36963283

Group type: EXPERIMENTAL
Intervention: COVID-19(+) cohort
Number of subjects: 196

Group type: COMPARATOR
Intervention: COVID-19(-) cohort
Number of subjects: 196
Study: 36963417

Group type: EXPERIMENTAL
Intervention: Active group (digital data informed treatment adjustments)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (pharmacy refill rates informed treatment adjustments)
Number of subjects: 220
Study: 36963502

Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: sTFR
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: FGF21
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: ferritin
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: collagen-X
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: CD14
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: RBP4
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: AGP
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: thyroglobulin
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Individual biomarkers
Number of subjects: 1120
Study: 36963504

Group type: EXPERIMENTAL
Intervention: % FFML at week 9
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Weight loss (WL) at week 9
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Weight regain at 1 year
Number of subjects: 70
Study: 36963515

Group type: EXPERIMENTAL
Intervention: Caring Contacts with introductory phone call (CC+)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Caring Contacts without introductory phone call (CC)
Number of subjects: 666
Study: 36963789

Group type: EXPERIMENTAL
Intervention: Oncologist-directed default palliative care referral orders (intervention arm)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual practice (control arm)
Number of subjects: 250
Study: 36963790

Group type: EXPERIMENTAL
Intervention: Interventions to reduce outdoor exposure to desert dust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions to reduce both outdoor and indoor exposure to particulate matter during desert dust episodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0